Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Glyco-Immune Checkpoint Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Siglec-9 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Siglec-9 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View Siglec-9 Products |
| Gene Delivery | Siglec-9 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Conformation preservation. |
View Siglec-9 Products |
| Benchmark Ab | Anti-Siglec-9 Biosimilar Recombinant positive control antibody for assay calibration. |
View Siglec-9 Products |
| Validator | Siglec-9 siRNA Set For target knockdown and specificity verification. |
View Siglec-9 Products |
| Related Target A | Siglec-7 High-homology counter-screening target to prevent off-target NK cell modulation. |
View Siglec-7 Products |
| Related Target B | Siglec-15 Synergistic myeloid checkpoint targeting tumor-associated macrophages (TAMs). |
View Siglec-15 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Off-Target Screening (Siglec-7/5/3) | High-purity homologous recombinant proteins verified by mass spectrometry and sequence analysis. |
| Sialic Acid Glycan-Binding Interference | HEK293 expression system guarantees native human glycosylation patterns, preserving physiological binding pockets. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live Siglec-9 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Siglec-9 therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies to glyco-immune checkpoint inhibitors, including sialidase-antibody conjugates and bispecifics. As first-generation therapies reach the clinic, the next wave of R&D is targeting tumor-specific sialoglycan-Siglec interactions to overcome resistance in cold tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Alethia Biotherapeutics, Jounce Therapeutics | Solid Tumors, Myeloid Leukemia | High-purity ECD-Fc proteins for high-throughput binding and blocking assays. |
| Sialidase-Fusion (Enzyme) | Palleon Pharmaceuticals | Ovarian Cancer, Colorectal Cancer | Native glycosylated Siglec-9 proteins to assess enzymatic desialylation efficiency. |
| Bispecific / Multi-specific | Academic & Biotech Consortia | Refractory Solid Tumors | Homology panel screening (Siglec-7/9) to ensure strict target selectivity. |